Navigation Links
89 North Wins Prestigious International Award
Date:2/6/2012

BURLINGTON, Vt., Feb. 6, 2012 /PRNewswire/ -- After only three years in business, 89 North won the prestigious 2011 Prism Award from the International Society for Optics and Photonics (SPIE) on Jan. 25. The award was for new products in the category of  "Life Sciences and Biophotonics."

The new product is 89 North's Heliophor, a patent-pending, innovative, high-intensity and exceptionally stable new light source used for quantitative fluorescence imaging in a wide variety of applications, including cancer research. A pumped-phosphor light engine, the Heliophor's stability and straightforward calibration system ensure that output intensity is consistent across measurements, allowing repeatable, truly quantitative fluorescent analysis.

The Prism Award was presented to 89 North at a gala banquet in San Francisco at SPIE's Photonics West Conference. SPIE gives the award "to products that challenge conventional ideas, solve problems, and improve life through the generation and harnessing of light."

SPIE was founded in 1955 to advance light-based technologies. Serving more than 180,000 constituents from 168 countries, the Society advances emerging technologies through interdisciplinary information exchange, continuing education, publications, patent precedent, and career and professional growth.

"The Heliophor provides a new alternative to arc lamps, metal halides, and LED light sources," SPIE said.

"The quality and competition among this year's entries was even keener than in past years," said SPIE CEO Eugene Arthurs. "More companies submitted applications than ever before. The strength of applications from core companies in our industry along with the impressive innovations bubbling up from smaller companies really demonstrates the vitality of the photonics industry."

89 North (www.89north.com), located in Burlington, Vermont, is a subsidiary of Bellow Falls' award-winning Chroma Technology Corp. (www.chroma.com). Chroma is a global employee-owned company manufacturing precision optical filters and coatings for biomedical instruments such as flow cytometers, plate readers and fluorescence microscopes.

"We created 89 North to encourage the kind of innovations that emerge when smart and creative people interact," said Chroma President Paul Millman. "The Prism award certifies the success of that interaction."

 

 


'/>"/>
SOURCE Chroma Technology Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
2. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
3. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
4. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
5. Test for Life Commends North Carolina Rules Commission for Implementing CDC Recommendations for HIV Testing
6. MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders
7. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
8. Northwestern Memorial Transplant Program Initiates New Study
9. Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program
10. Northwestern Memorial Study Tests Cancer Drug on Scleroderma Patients
11. Northern California Foot and Ankle Center Santa Rosa Enrolling Patients With Chronic Diabetic Foot Ulcers for Matrix Clinical Research Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... and EDMONTON, Alberta , ... scientists and the University of Alberta in ... data in Nature,s partner journal, Schizophrenia 1 , ... predict instances of schizophrenia with 74% accuracy. This ... severity of specific symptoms in schizophrenia patients with ...
(Date:7/21/2017)... Did you know that PhRMA member companies invested $65.5 billion in ... brand medicines, generics and the supply chain account for 14 percent ... of this (7 percent)? Or that the United States ... investments in high-growth biopharmaceutical startups? ... The biopharmaceutical industry accounts ...
(Date:7/17/2017)... Fla. , July 17, 2017  MedX Holdings, ... branded medical testing, strengthening and rehabilitation equipment, today announced ... Machine Program. MedX is considered the gold standard for ... leader in specialized medical strengthening equipment. ... a lease with the physician or practice who prescribe ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... ... effectively destroyed the construction site and threatened numerous homes and businesses nearby, causing ... article on NBCLosAngeles.com. Los Angeles Area consulting firm Fire Protection Group, Inc. ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... Axiad ... organizations, today announced it has partnered with WALLIX to expand its solution ... 800-171 . , There are a number of ways to address the authentication requirements ...
(Date:7/24/2017)... ... 24, 2017 , ... Puregraft, the global leader in the ... United States Patent Number 9,695,398 (the '398 patent) and South Korean Patent Number ... '324 patents cover methods and systems for optimizing fat grafts for current and ...
(Date:7/24/2017)... ... 2017 , ... A new report released today by FusionHealth, ... health care at scale, indicates record-breaking adherence results for the company’s obstructive sleep ... pressure (PAP) therapy, the most widely utilized treatment for OSA, typically range between ...
(Date:7/24/2017)... ... July 24, 2017 , ... Committed to eliminating ... enrolled over 100,000 children in their treatment program. Clubfoot is a pervasive problem ... where treatment is limited or non-existent. Without intervention, these children are destined to ...
Breaking Medicine News(10 mins):